Download Files:
LY2857785
$132 – $2,520
Products Details
Product Description
– LY2857785 is a type I reversible and competitive ATP kinase inhibitor against CDK9 (IC50 11 nM) and other transcription kinases CDK8 (IC50 16 nM), and CDK7 (IC50 246 nM).
Web ID
– HY-12293
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C26H36N6O
References
– [1]Yin T, et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. Mol Cancer Ther. 2014 Jun;13(6):1442-56. Mol Cancer Ther. 2014 Jun;13(6):1442-56.
CAS Number
– 1619903-54-6
Molecular Weight
– 448.60
Compound Purity
– 99.92
SMILES
– CC(C1=C2C=C(C3=NC(N[C@H]4CC[C@H](NC5CCOCC5)CC4)=NC=C3)C=CC2=NN1C)C
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 10 mg/mL (ultrasonic)
Target
– Apoptosis;CDK
Isoform
– CDK7;CDK8;CDK9
Pathway
– Apoptosis;Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
